Imidapril

Imidapril
Systematic (IUPAC) name
	(4S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid
Clinical data
AHFS/Drugs.com	International Drug Names
Identifiers
CAS Number	89371-37-9
ATC code	C09AA16 (WHO)
PubChem	CID 5464343
IUPHAR/BPS	6377
ChemSpider	4576628
UNII	BW7H1TJS22
KEGG	D08068
ChEMBL	CHEMBL317094
Chemical data
Formula	C20H27N3O6
Molar mass	405.444 g/mol
3D model (Jmol)	Interactive image
	SMILES O=C(O)[C@H]2N(C(=O)[C@@H](N[C@H](C(=O)OCC)CCc1ccccc1)C)C(=O)N(C)C2 ;
	InChI InChI=1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1 ; Key:KLZWOWYOHUKJIG-BPUTZDHNSA-N ;
(what is this?) (verify)

Imidapril (INN) is an ACE inhibitor used as an antihypertensive drug and for the treatment of chronic heart failure.^[1]

Imidaprilat — the active metabolite of imidapril

References[edit]

^ Robinson, D. M.; Curran, M. P.; Lyseng-Williamson, K. A. (2007). "Imidapril: A review of its use in essential hypertension, Type 1 diabetic nephropathy and chronic heart failure". Drugs. 67 (9): 1359–1378. doi:10.2165/00003495-200767090-00008. PMID 17547476.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

v t e Antihypertensives: agents acting on the renin–angiotensin system (C09)

ACE inhibitors ("-pril")	Sulfhydryl-containing: Captopril Rentiapril Zofenopril Dicarboxylate-containing: Enalapril^# Benazepril Cilazapril Delapril Imidapril Lisinopril (+HCT) Moexipril Perindopril (+indapamide) Quinapril (+HCT) Ramipril Spirapril Temocapril Trandolapril Phosphonate-containing: Fosinopril (+HCT) Other/ungrouped: Alacepril

AIIRAs ("-sartan")	Azilsartan Candesartan Eprosartan Fimasartan Irbesartan Losartan (+HCT) Olmesartan (+amlodipine) Tasosartan^§ Telmisartan (+HCT) Valsartan (+HCT, +amlodipine, +sacubitril)

Renin inhibitors ("-kiren")	Aliskiren (+amlodipine, +amlodipine and HCT) Remikiren^§

^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III